GlaxoSmithKline Plc said a Phase 3 trial of its candidate vaccine against the Ebola virus is set to start in Liberia in the coming weeks, subject to regulatory approval. The trial is being led by the US National Institutes of Health, which is a co-developer of the vaccine.
